Letter From the Editors
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
Oncology Ethics Forum
Ethical Perspectives on Oncology Care
By Terri Maxwell, RN, MSN, AOCN
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
Development of Antagonists of the Platelet-Derived Growth Factor Receptor Family
By Neill A. Giese, PhD, Nathalie A. Lokker, PhD, Jin-Chen Yu, PhD, Kenji Matsuno, PhD, Michio Ichimura, PhD, Shoji Oda, PhD, Robert Scarborough, PhD, and Anjali Pandey, PhD
STI571: A Sea Change in Cancer Therapeutics or a One Time Event?
By Brian J. Druker, MD
Pharmacy Practice
The Role of Chemoprotectants in Cancer Supportive Care
By Masha S. H. Lam, PharmD, and Robert J. Ignoffo, PharmD, FASHP
Development of STI571 and Its Use in Chronic Myelogenous Leukemia and Other Malignancies
By Michael J. Mauro, MD, Michael E. O’Dwyer, MD, and Brian J. Druker, MD
Understanding the Genotoxicity of Tamoxifen?
By David H. Phillips, DSc, MRCPath
Lymphomas – The Diseases That Taught Us Monoclonal Antibodies Can Work
The Expanding Indications for Preimplantation Genetic Diagnosis
By Steven Joffe, MD, MPH
New Strategies for the Treatment of Indolent Non-Hodgkin’s Lymphomas
By Blanche H. Mavromatis, MD, and Bruce D. Cheson, MD
The Important Role of Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphomas
By Antonio J. Grillo-López, MD
The Role of Radiation Therapy in Hodgkin’s Lymphoma
By Matthew C. Hull, MD, and Nancy Price Mendenhall, MD
Management of Aggressive Lymphoma
By Koen van Besien, MD, and Katarzyna Finiewicz, MD
DASS21
Geriatric Depression Scale (Long Form)